STRONGBRIDGE BIOPHARMA plc Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2019-12-16: Study NCT04212000; Company role Lead sponsor; Phase Phase 1; Status Completed.
- 2019-03-28: Study NCT03880825; Company role Lead sponsor; Phase Phase 1; Status Completed.
- 2019-01-07: Study NCT03621280; Company role Lead sponsor; Phase Phase 3; Status Completed.
- 2018-11-30: Study NCT03768388; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2019-12-16 | NCT04212000 Bioavailability of Levoketoconazole and Ketoconazole Tablets | Lead sponsor | Phase 1 | Completed | Healthy | 34 | 2020-01-23 |
| 2019-03-28 | NCT03880825 Drug Interaction Study of Levoketoconazole and Metformin | Lead sponsor | Phase 1 | Completed | Healthy Subjects | 32 | 2019-05-03 |
| 2019-01-07 | NCT03621280 Open-label Treatment in Cushing's Syndrome | Lead sponsor | Phase 3 | Completed Results posted | Cushing Syndrome; Cushing Disease | 51 | 2022-12-31 |
| 2018-11-30 | NCT03768388 Levoketoconazole Food Effect Study in Healthy Subjects | Lead sponsor | Phase 1 | Completed | Healthy Subjects | 22 | 2018-12-24 |
| 2017-09-26 | NCT03277690 A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome. | Lead sponsor | Phase 3 | Completed Results posted | Endogenous Cushing's Syndrome | 84 | 2020-08-31 |
| 2014-08 | NCT01838551 Treatment for Endogenous Cushing's Syndrome | Lead sponsor | Phase 3 | Completed Results posted | Endogenous Cushing's Syndrome | 94 | 2018-11 |